company background image
82P logo

Pacira BioSciences DB:82P Stock Report

Last Price

€19.20

Market Cap

€896.8m

7D

5.5%

1Y

-28.9%

Updated

12 Dec, 2024

Data

Company Financials +

82P Stock Overview

Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. More details

82P fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Pacira BioSciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pacira BioSciences
Historical stock prices
Current Share PriceUS$19.20
52 Week HighUS$32.20
52 Week LowUS$10.70
Beta0.80
1 Month Change20.75%
3 Month Change62.71%
1 Year Change-28.89%
3 Year Change-62.35%
5 Year Change-53.62%
Change since IPO301.76%

Recent News & Updates

Recent updates

Shareholder Returns

82PDE PharmaceuticalsDE Market
7D5.5%2.6%0.3%
1Y-28.9%-10.8%9.6%

Return vs Industry: 82P underperformed the German Pharmaceuticals industry which returned -7.8% over the past year.

Return vs Market: 82P underperformed the German Market which returned 10.3% over the past year.

Price Volatility

Is 82P's price volatile compared to industry and market?
82P volatility
82P Average Weekly Movement6.5%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 82P has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 82P's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006712Frank Leewww.pacira.com

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.

Pacira BioSciences, Inc. Fundamentals Summary

How do Pacira BioSciences's earnings and revenue compare to its market cap?
82P fundamental statistics
Market cap€896.84m
Earnings (TTM)-€86.68m
Revenue (TTM)€663.96m

1.3x

P/S Ratio

-10.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
82P income statement (TTM)
RevenueUS$694.96m
Cost of RevenueUS$255.38m
Gross ProfitUS$439.58m
Other ExpensesUS$530.31m
Earnings-US$90.73m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.97
Gross Margin63.25%
Net Profit Margin-13.06%
Debt/Equity Ratio78.4%

How did 82P perform over the long term?

See historical performance and comparison